Quest Diagnostics Inc. closed 8.75% short of its 52-week high of $182.38, which the company achieved on June 16th.

An appellate panel shut down a lawsuit from a compliance officer at Quest Diagnostics Inc. claiming the lab ran a fraudulent billing scheme for unnecessary tests.

Quest Diagnostics (DGX) is a strong buy with growth potential, solid margins, and dividend increases. Discover the full ...

While clinical laboratory Quest Diagnostics (DGX) had a rough outing last week, speculators seeking a discount may want to ...

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June ...

New York Giants rookies officially report for training camp on Tuesday, one week ahead of the remainder of the team.

Former Seattle Seahawks quarterback Russell Wilson will begin his first training camp with the New York Giants. As he begins work with his third team in three s ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Quest Diagnostics Inc. closed 5.99% below its 52-week high of $182.38, which the company achieved on June 16th.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...